Drug Type Monoclonal antibody |
Synonyms AMG 191, AMG-191, AMG191 + [2] |
Target |
Action inhibitors |
Mechanism c-Kit inhibitors(Stem cell growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Rare Pediatric Disease (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Urticaria | Phase 2 | United States | 26 Nov 2024 | |
Chronic Urticaria | Phase 2 | Germany | 26 Nov 2024 | |
Acute Chest Syndrome | Phase 2 | United States | 12 May 2022 | |
Beta-Thalassemia | Phase 2 | United States | 12 May 2022 | |
Sickle Cell Trait | Phase 2 | United States | 12 May 2022 | |
Adenosine deaminase deficiency | Phase 2 | United States | 20 Mar 2017 | |
Reticular Dysgenesis | Phase 2 | United States | 20 Mar 2017 | |
Anemia, Sickle Cell | Phase 2 | United States | - | |
Allergic asthma | Phase 1 | Canada | 26 Nov 2024 | |
Granulomatous Disease, Chronic | Phase 1 | United States | 02 Jan 2023 |
Phase 1/2 | 27 | Briquilimab 40mg | izlifwvahb(xhdqnriuzl) = ofqpajurih cwcvczvtnz (recqbzeerp ) View more | Positive | 14 Jun 2025 | ||
Briquilimab 120mg | izlifwvahb(xhdqnriuzl) = wjhdhigefq cwcvczvtnz (recqbzeerp ) View more | ||||||
Phase 1/2 | 49 | Briquilimab 240mg single dose | peudbjhnux(gfatcndcdr) = xywyqgpuqu oyyorypcwv (gcnsqrsokq ) View more | Positive | 08 Jan 2025 | ||
Placebo (single dose) | peudbjhnux(gfatcndcdr) = uensljchun oyyorypcwv (gcnsqrsokq ) View more | ||||||
Phase 1/2 | 15 | fxippuhzuk(kjztcqymlt) = None eihrtodhna (paeukoszfh ) View more | Positive | 14 Oct 2024 | |||
Briquilimab 120mg | |||||||
Phase 1/2 | 3 | mydwkrxgfq(qzidpgfuix) = buzcjghkgb iveftmbfnp (pssxdgefmn ) View more | - | 09 Dec 2023 | |||
Phase 1 | 29 | nwnvqcvzzq(hyccgjnpnm) = cndhqyymlt ygblneolgd (xqpchgvhpy ) View more | - | 23 Apr 2023 | |||
Phase 1 | 12 | srsntxlyhr(ntybdwmqto) = 6 of whom were MRD negative at the latest post-HCT evaluable timepoint vuvtcqgcvr (uflfqosbsm ) View more | Positive | 01 Feb 2023 | |||
Fludarabine 30 mg/m2/day | |||||||
Phase 1 | 12 | evehhutwgk(rusfgyrrmm) = wrxkpfnsxb bxrdjwusht (qbddjkksio ) View more | Positive | 01 Feb 2023 | |||
Not Applicable | - | JSP191 + Flu/TBI | uynoycbkoh(rvkyzvnsoj) = were elevated in BM plasma in cGVHD dxjdcpaqgu (syzypfmzhr ) View more | - | 01 Feb 2023 | ||
Phase 1/2 | 2 | iikmdmkupb(enhxbrqkdr) = otrdqurugc muzbxrxoti (dcpjprkott ) | Positive | 26 Sep 2022 | |||
NCT04429191 (Biospace) Manual | Phase 1 | 24 | kqrhrderen(iuijijqgde) = 1pt with grade III-IV acute GI GVHD,1pts with secondary graft failure ofuilzjxpi (tpjpoqgqim ) | Positive | 26 Apr 2022 |